Trials / Completed
CompletedNCT06707181
Comparative Study for Medical Therapy for Lower Ureteral Stones
Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Beni-Suef University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to compare the efficacy and adverse effects of different drugs as a medical expulsive therapy for lower ureteral stones. The main questions it aims to answer are: * Which of the following are more effective silodosin, tamsulosin, silodosin plus tadalafil and tamsulosin plus tadalafil as a therapy for lower ureteral stones? * What medical problems do participants have when taking these drugs? Researchers will compare silodosin, tamsulosin, silodosin plus tadalafil and tamsulosin plus tadalafil to see which drug works better to treat lower ureteral stones Participants will: * Take silodosin, tamsulosin, silodosin plus tadalafil or tamsulosin plus tadalafil every day for 28 days * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf | • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days. |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2024-05-20
- Completion
- 2024-08-18
- First posted
- 2024-11-27
- Last updated
- 2024-11-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06707181. Inclusion in this directory is not an endorsement.